Clinical Trials

Please note that our clinical trials are currently only available to patients receiving care in Australia.
Unfortunately, we are unable to enrol international patients at this time.
OPEN for recruitment

AP601

A Study of AP601 in patients with locally unresectable advanced or metastatic solid tumours.

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Bi-specific antibody targeting CD73 and CD137 (AP601), administered via IV.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill)

OPEN for recruitment

BNT3214-01

Early-phase trial to assess the safety and preliminary efficacy of BNT3214 in adults with advanced solid tumors.

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: BNT3214, a bi-specific antibody-drug conjugate (administered via IV)

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill)

OPEN for recruitment

DINE-PC

Dietetics Intervention and Nutritional Evaluation in Pancreatic Cancer Care (DINE-PC).

Diagnosis: Pancreatic cancer.

Treatment: Dietetics counselling.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill), Epworth Geelong.

OPEN for recruitment

FMT

Fecal Microbiota Transplantation to improve pain, symptom management and treatment efficacy in patients with pancreatic cancer

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Fecal Microbiota capsules (oral) in combination with chemotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

KANDLELIT

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014).

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Calderasib (MK-1084; oral KRASG12C covalent inhibitor) +/- Cetuximab (IV).

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill)

OPEN for recruitment

NeoFOL-R

Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicentre prospective randomized, controlled trial (NeoFOL-R).

Diagnosis: Resectable pancreatic ductal adenocarcinoma.

Treatment: Surgery with mFOLFIRINOX chemotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

PemOla

A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with mismatch repair deficiency or tumour mutation burden > 4 Mutations/Mb.

Diagnosis: Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Pembrolizumab (PD1 inhibitor) with Olaparib (PARP inhibitor).

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill)

CLOSED for recruitment

ACCENT (AMP945-PC-201)

A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients.

Diagnosis: Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Focal adhesion kinase (FAK) inhibitor AMP945 (oral) given prior to dosing with nab-paclitaxel and gemcitabine in first-line setting.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

AMG193 20210023

AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination with Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (MTAP)

Diagnosis: Locally advanced (Stage III) unresectable or metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: PRMT5 inhibitor AMG193 (oral) monotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

AMG193 20230223

A Study Evaluating AMG 193 in Combination with Other Therapies in Participants with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers with Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: AMG193 (PRMT5 inhibitor) + RMC-6236 (pan-RAS inhibitor)

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

AMPLICITY (AMP945-202)

A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer.

Diagnosis: Metastatic (Stage IV) pancreatic ductal adenocarcinoma

Treatment: Focal adhesion kinase (FAK) inhibitor AMP945 (oral) given prior to dosing with FOLFIRINOX (chemotherapy)

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

ASCEND

A Randomised, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Diagnosis: Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

DIRECT-InspIRE Australia

Investigation of the safety and efficacy of irreversible electroporation (IRE) using the NanoKnife® System in patients with unresectable stage 3 pancreatic cancer who have received 3 months of chemotherapy.

Diagnosis: Locally advanced (Stage III) unresectable pancreatic ductal adenocarcinoma.

Treatment: Irreversible Electroporation (IRE) with the NanoKnife system (surgical).

Epworth locations: Epworth Freemasons (East Melbourne).

CLOSED for recruitment

MK9999

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers.

Diagnosis: Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: TROP2 inhibitor MK-2870 monotherapy or in combination with chemotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

Porcupine P2EA

An open-label study to assess the preliminary efficacy and safety of RXC004, (Zamaporvint), in patients with advanced pancreatic cancer who have progressed following therapy with current standard of care. 

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma

Treatment: RXC004 (Zamaporvint) oral monotherapy in combination with denosumab

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill)

CLOSED for recruitment

SPEAR

A Phase 2, Open-Label, Single-Arm Sulfasalazine Monotherapy Trial of Progression-Free Survival In Patients with Pancreatic Adenocarcinoma.

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Sulfasalazine monotherapy (oral).

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne).

CLOSED for recruitment

SuperQoL

Supplemental Jejunal feeding to Improve Quality of Life (SuperQoL).

Diagnosis: Locally advanced (Stage III) unresectable or metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: Dietetics counselling.

Epworth locations: Epworth Richmond.

CLOSED for recruitment

TRIPP-FFX

An open-label, multi-centre, randomized study of Targeted Radioactive Intratumoural Placement of Phosphorous-32 (OncoSil™) in addition to FOLFIRINOX chemotherapy versus FOLFIRINOX chemotherapy alone in patients with unresectable locally advanced pancreatic adenocarcinoma.

Diagnosis: Locally advanced (Stage III) unresectable pancreatic ductal adenocarcinoma.

Treatment: P32 Oncosil (brachytherapy device) in combination with mFOLFIRINOX chemotherapy.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

CLOSED for recruitment

YH003004

A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/ metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC).

Diagnosis: Locally advanced (Stage III) unresectable or Metastatic (Stage IV) pancreatic ductal adenocarcinoma.

Treatment: YH003 (recombinant humanized agonistic CD40 IgG2 mAb) in combination with Toripalimab (anti-PD-1 mAb) with or without nab-paclitaxel + gemcitabine.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

Research Studies

OPEN for recruitment

APCR

Australasian Pancreatic Cyst Registry

Diagnosis or condition: Individuals diagnosed with Intraductal papillary mucinous neoplasms (IPMN)

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne).

OPEN for recruitment

APRISE

The Australian Pancreatic High-RIsk ScrEening (APRISE) Study 

Diagnosis or condition: Individuals considered at high-risk of developing pancreatic cancer. 

Epworth locations: Epworth Richmond.

OPEN for recruitment

MoST

Molecular Screening and Therapeutics Program (MoST)

Diagnosis or condition: Pancreatic cancer. 

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

SCANPatient

Synoptic reporting of CT scans assessing cancer of the pancreas 

Diagnosis or condition: Suspected diagnosis of pancreatic cancer. 

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne).

OPEN for recruitment

PaCaSo

The Australian and Aotearoa New Zealand Pancreatic Cancer Surgical Outcomes (PaCaSO) Registry

Diagnosis or condition: Individuals who have experience of pancreatic cancer surgery, as a patient, carer, or loved one.

Epworth locations: Epworth Richmond.

OPEN for recruitment

PCB

Pancreaticobiliary Cancer Biobank (PCB)

Diagnosis or condition: Suspected diagnosis of pancreatic cancer or cholangiocarcinoma. 

Epworth locations: Epworth Richmond.

OPEN for recruitment

PEISS

Validation of a patient-reported symptom tool to identify pancreatic exocrine insufficiency in pancreatic cancer.

Diagnosis or condition: Pancreatic cancer.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

OPEN for recruitment

PERT registry

A national patient reported registry to understand the experience of taking pancreatic enzyme replacement therapy for people diagnosed with pancreatic cancer.

Sponsor: The University of Otago

Diagnosis or condition: Pancreatic cancer

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill)

OPEN for recruitment

PRB

Pancreatic Research Biobank

Diagnosis or condition: Pancreatic diseases, including pancreatic cancer, pancreatic cysts, chronic pancreatitis, and related metabolic conditions such as diabetes.

Epworth locations: Epworth Richmond.

CLOSED for recruitment

OSCILLATE

An Observational Study following Circulating tumour DNA during multi-Agent Therapy in PDAC (OSCILLATE)

Diagnosis or condition: Unresectable pancreatic cancer.

Epworth locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).